Drug Trial Radar · NCT07361549
Localized Injection of Lidocaine Via the Middle Meningeal Artery for Headache Treatment
Last checked: Nov 20, 2026Latest source record: Oct 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Sep 9, 2026
Primary completion
Dec 2030
Study completion Jul 2031
Sponsor
- Lead sponsor
- Daniel A Tonetti, MDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- SNIS Foundation; Stryker Neurovascular
- First posted
- Jan 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to test whether injecting lidocaine into two blood vessels of the brain can help treat chronic headaches (migraines)
Conditions
- Refractory Migraine
- Headache
Interventions
Lidocaine (drug)Drug
Intra-arterial lidocaine infusion into bilateral middle meningeal arteries
SalineDrug
Intra-arterial saline infusion into bilateral middle meningeal arteries
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Headache Impact Test-6 Scores (1 Month)Time frame: From baseline to 1 month follow-up
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cooper University Health Care
Camden, New Jersey · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.